- 期刊
Extended-Release Carvedilol in the Treatment of Hypertension: A Double-Blind, Randomized, Placebo-Controlled Trial
摘要
Background: Immediate-release carvedilol requires twice-daily dosing and may have low treatment compliance. We assessed the efficacy of a new formulation of once-daily extended-release carvedilol (carvedilol ER) on systolic blood pressure (SBP) and diastolic blood pressure (DBP) among patients with hypertension in this double-blind, randomized, placebo-controlled trial. Methods: A total of 134 patients with untreated or uncontrolled hypertension were randomly assigned in a 1:1:1 ratio to receive placebo, low-dose carvedilol ER, or high-dose carvedilol ER for 8 weeks. The primary endpoint was the reduction in office SBP at 8 weeks. Secondary endpoints included the reduction in office DBP and the proportion of patients with blood pressure (BP) ＜ 140/90 mm Hg. Results: In the intention-to-treat population, placebo-adjusted changes in SBP/DBP were -2.9mmHg [95% confidence interval (CI), -9.6 to 3.7]/-1.7mmHg (95% CI, -5.6 to 2.3) and -4.9mmHg (95% CI, -11.5 to 1.7)/-3.4mmHg (95% CI, -7.3 to 0.5) for low-dose carvedilol ER and high-dose carvedilol ER, respectively. In the per-protocol population, high-dose carvedilol ER was associated with a significant DBP reduction [placebo-adjusted difference, -4.7 mm Hg (95% CI, -8.8 to -0.5); adjusted p = 0.026]. There was a gradational improvement in BP control with carvedilol ER (25%, 37%, and 48% for placebo, low-dose carvedilol ER, and high-dose carvedilol ER, respectively; linear-by-linear association p = 0.028). There were no differences in safety among the three groups. Conclusions: Carvedilol ER, though well tolerated, did not result in a greater reduction in either SBP or DBP compared with placebo.
延伸閱讀
- 洪芳玲（2003）。The Effectiveness of Applying Case Management for Patients with Hypertension at an Outpatient Department〔碩士論文，臺北醫學大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0007-1704200714522876
- 洪麗玲、洪麗珍、張彩秀（2011）。Effectiveness of Using a Tele-Health Care System on Self-Management Behaviors of Patients with Hypertension。醫療資訊雜誌，20(3)，53-65。https://doi.org/10.29829/TJTAMI.201112.0004
- Hwang, Y. S., & Tsai, K. Y. (2011). Irbesartan/Hydrochlorothiazide Fixed Combination Therapy in Systemic Hypertension: An Open-Label Uncontrolled Trial. 南臺灣醫學雜誌, 7(2), 70-78. https://doi.org/10.6726/MJST.201112_7(2).0001
- Papademetriou, V., Doumas, M., Faselis, C., Tsioufis, C., Douma, S., Gkaliagkousi, E., & Zamboulis, C. (2011). Carotid Baroreceptor Stimulation for the Treatment of Resistant Hypertension. International Journal of Hypertension, 2011(), 286-290. https://doi.org/10.4061/2011/964394
- Collinson, N., Tuckwell, K., Habeck, F., Chapman, M., Klearman, M., & Stone, J. H. (2015). Development and Implementation of a Double-Blind Corticosteroid-Tapering Regimen for a Clinical Trial. International Journal of Rheumatology, 2015(), 72-77. https://doi.org/10.1155/2015/589841